Otsuka has now formally decided to terminate the development of AVP-786 for Alzheimer's agitation, for which it is set to book another JPY100bn loss this year, and marking a major setback for an asset that was a key attraction in a previous large acquisition.
Otsuka Pharmaceutical Co. Ltd. has now decided to fully terminate the development of its neuropsychiatric compound AVP-786 following a Phase III failure reported earlier this year.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.
Start-ups from China dominated the fastest-growing share prices for mid-cap biopharma companies in Q1, while the biggest decliners were mainly US firms.
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
